The stock price of CRISPR Therapeutics, a biotechnology gene editing company focused on developing gene-based medicines for human diseases, reached an all-time high of $210 in January of this year before a gradual decline drove the stock price down over 60% to its current level of around $80...
The stock price of CRISPR Therapeutics, a biotechnology gene editing company focused on developing gene-based medicines for human diseases, reached an all-time high of $210 in January of this year before a gradual decline drove the stock price down over 60% to its current level of around $80...
Share this Article
Recommended